Calciferol BD

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Calciferol BD

Property Description
Active ingredient Dihydrotachysterol (DHT)
Form Tablets or Oral Solution
Pharmacological class Vitamin D Analog, Calcium Regulator
General purpose Supports Mineral Homeostasis and acts as an Anti-tetany Substance
Origin Synthetic (Seco-steroid)

What Type of Medicine is Calciferol BD and Its Active Component?

Calciferol BD is a single active ingredient pharmacological preparation that belongs to the clinical class of Vitamin D and analogues. Its core substance is Dihydrotachysterol (DHT), which functions as a Calcium Regulator. This medicine is designed for the oral route of administration and is typically available in standard dosage forms such as tablets or a concentrated oral solution. The product is recognized by medical professionals for its role in rapidly helping to restore calcium balance.

Is Dihydrotachysterol a Natural or Synthetic Substance?

The active component, Dihydrotachysterol, is defined as a synthetic seco-steroid, a structure that differentiates it from naturally occurring Vitamin D forms like Cholecalciferol (Vitamin D3). This synthetic origin grants the substance a specific functional advantage: DHT is engineered to be renal-activation independent. This means it requires only one metabolic step in the liver to become biologically active, bypassing the second, mandatory hydroxylation step normally required in the kidney for the full activation of the parent Vitamin D molecule.

What is the General Purpose of This Vitamin D Analog?

The general purpose of Calciferol BD is to maintain stable mineral homeostasis throughout the body, supporting essential neuromuscular and skeletal functions. By efficiently promoting the intestinal absorption of calcium and phosphate and facilitating the mobilization of calcium from bone, the medication acts as an effective anti-tetany substance. This action is clinically recognized for its direct role in helping to prevent the neuromuscular symptoms associated with severe calcium deficiencies, serving as a reliable bone density conservation agent.

What side effects are possible with Calciferol BD?

Possible side effects and safety information

The safety profile of Calciferol BD (Dihydrotachysterol) is primarily defined by its potential to cause Hypercalcemia (abnormally high blood calcium levels), which is the principal adverse reaction documented in official regulatory sources. Adverse reactions are generally symptomatic of this elevated calcium level.


Documented Adverse Reactions

Side effects are grouped by the affected system-organ class in regulatory texts. Early signs of hypercalcemia, which can be Very Common according to the classification used for Vitamin D analogues, may include:

  • Gastrointestinal and Systemic Disorders: Nausea, vomiting, loss of appetite (Anorexia), weight loss, fatigue, metallic taste, and constipation.
  • Fluid Balance: Excessive thirst (Polydipsia) and increased frequency of urination (Polyuria).
  • Neurological and Musculoskeletal Disorders: Headache, muscle pain, bone pain, weakness, and vertigo.

Serious Safety Concerns

More severe or prolonged hypercalcemia is associated with serious adverse reactions that affect major organ systems, as documented in official prescribing information:

  • Renal Damage: Impairment of kidney function, including Nephrocalcinosis (calcium deposits in the kidneys), and potentially renal failure.
  • Cardiac Events: Disturbances in heart rhythm (Cardiac Arrhythmias) and high blood pressure (Hypertension).
  • Metastatic Calcification: Widespread abnormal calcification of soft tissues throughout the body, including blood vessels and lungs.

Safety Considerations and Restrictions

Official safety documents explicitly state that the medication is contraindicated in patients who already have Hypercalcemia or Hypervitaminosis D. Furthermore, the toxic effects of overdosage have been noted to persist for up to one month after treatment is discontinued. The medicine is classified as Pregnancy Category C, advising caution, and the label contains specific notes regarding the risk of metastatic calcification in patients with kidney conditions, requiring careful monitoring of phosphorus levels.

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information for Calciferol BD

Overdose scope

Feature Official Regulatory Statements
Documented overdose presentations The primary presentation is characterized by hypercalcaemia, which may manifest with early symptoms including nausea, vomiting, headache, anorexia, polyuria, and polydipsia.
Physiological systems affected (as stated in label) Cardiovascular system (e.g., cardiac arrhythmias), Central Nervous System (e.g., seizures, coma), and Renal System (e.g., nephrocalcinosis, renal failure).
Dose-related or exposure-related factors Prolonged, excessive administration can lead to the most severe forms of toxicity, potentially causing widespread soft tissue calcification.
Population-specific overdose notes Infants exposed through maternal use must be monitored for hypercalcaemia signs.
Emergency-response statements Overdose treatment begins with the immediate withdrawal of the medicine. Patients should contact a regional Poison Control Centre immediately.
When immediate medical help is required Severe hypercalcaemia or a hypercalcaemic crisis—particularly when presenting with dehydration, stupor, or coma—requires more vigorous treatment and urgent medical attention.

Overdose classifications (high-level)

Classification Official Regulatory Statements
Severity classification Hypercalcaemic crisis is identified as the most severe acute classification, potentially resulting in death from cardiovascular or renal failure.
Regulatory basis Based on the U.S. Food and Drug Administration (FDA) Prescribing Information and European Summary of Product Characteristics (SmPC) for this class of medicine.
Overdose-context constraints No specific chemical antidote is listed. Management relies on procedural steps and supportive measures.

Resulting overdose structure

Official overdose statements:

  • The core toxicity is established as hypercalcaemia, documented to progress from early non-specific symptoms to severe complications like cardiovascular and renal impairment.
  • Severe overdose requires immediate withdrawal of the medicine and initiation of specific supportive treatments, including intravenous saline hydration and institution of a low-calcium diet.
  • Monitoring during management requires regular determination of blood calcium levels, alongside checks of renal function and ECG in severe cases.

Connection to the overall overdose profile (3 sentences):

Regulatory documents define the Dihydrotachysterol overdose profile strictly by its resulting pathology: a state of severe hypercalcaemia that carries a documented risk of serious systemic damage to the cardiovascular and renal systems. This profile dictates the non-antidotal emergency management strategy, which relies on discontinuing the drug and initiating procedural steps like intravenous hydration and calcium monitoring to reverse the effects. The requirement to seek immediate medical help is explicitly tied to the onset of severe hypercalcaemic symptoms or crisis.

Therapeutic Uses of Calciferol BD

Calciferol BD is used to address or prevent states of vitamin D deficiency. This is a common clinical scenario for individuals with limited sun exposure, certain dietary restrictions, or conditions that affect nutrient absorption. The main purpose is to support bone health and assist in maintaining calcium and phosphate balance within the body.***

It is often utilized as a component of care for bone conditions linked to insufficient vitamin D, including rickets (bone softening in children), osteomalacia (bone softening in adults), and to provide general support for bone density in cases like osteoporosis.***

Quick Fact: May support Musculoskeletal Function Calciferol BD is intended to provide nutritional support and may help manage muscle weakness or bone discomfort associated with prolonged deficiency, contributing to the maintenance of normal muscle function.***

Regulatory References

  1. NIH MedlinePlus Cholecalciferol overview

Eligibility and Restrictions for Use

Eligibility Scope

Populations for whom use is contraindicated: Use of Calciferol BD is strictly prohibited for individuals who have pre-existing high calcium levels (Hypercalcaemia) or an excess of Vitamin D (Hypervitaminosis D). The medicine is also contraindicated for breastfeeding mothers, due to the risk of transferring the substance to the infant, and for patients with known hypersensitivity to the active ingredient or any excipients.

Age-related eligibility rules: The use of this medicine is established and permitted for all major age groups, including neonatal, pediatric, and adult populations, for officially approved therapeutic needs. There are no absolute age-related restrictions that prohibit its use across these groups.

Condition-specific eligibility rules and restrictions: Use during pregnancy is restricted and conditional; it is only allowed if a formal assessment determines that the potential benefits clearly outweigh the possible risks. Patients with Sarcoidosis require special caution and close monitoring, as their condition may increase their sensitivity to Vitamin D analogues. Official regulatory data for specific dose adjustments related to Renal or Hepatic Impairment are not available.

Connection to the Overall Eligibility Profile

The regulatory profile strictly defines eligibility through metabolic exclusions, formally contraindicating use in hypercalcemic states and during lactation. For populations where use is permitted, such as adults and children, it is tied only to approved conditions, while conditional use rules are applied to manage the unique risks associated with pregnancy and comorbid sensitivities.

What should I know about interactions with other medicines?

The interaction profile for Calciferol BD (Dihydrotachysterol) is structured according to its effects on calcium homeostasis and its metabolic fate, as documented in official government regulatory labeling.

Official Regulatory Restrictions

Regulatory authorities classify the co-administration of calcium supplements as contraindicated due to the significant, enhanced risk of hypercalcaemia.

Pharmacodynamic and Toxicity Risk

Interactions involving additive effects are clearly documented. Thiazide diuretics may enhance the calcaemic response of Dihydrotachysterol, requiring caution due to potential hypercalcaemia. Furthermore, the risk of hypercalcaemia associated with this medicine may enhance the toxic effects of cardiac glycosides, a specific warning present in official prescribing information.

Metabolic and Exposure-Modifying

A number of medicines are documented to alter the exposure of Dihydrotachysterol. Medicines known to accelerate clearance, including the anticonvulsants phenytoin and phenobarbital, along with rifampicin and isoniazid, may reduce the overall effectiveness of Calciferol BD. Absorption-interfering substances, such as the bile acid sequestrant cholestyramine, are formally documented to impair intestinal absorption. Similarly, co-administration with thyroid replacement therapy may increase the clearance of the medicine. These statements describe specific, label-based interaction outcomes.

Mechanism of Action

Calciferol (cholecalciferol, Vitamin D3) functions as a prohormone. Following systemic absorption, it is first hydroxylated in the liver by 25-hydroxylase (CYP2R1) to form calcidiol (25-hydroxycholecalciferol). Calcidiol then undergoes a second hydroxylation, primarily in the renal tubules by the enzyme 1-alpha-hydroxylase (CYP27B1), yielding the biologically active hormonal form, calcitriol (1,25-dihydroxycholecalciferol).

Calcitriol acts as a transcription factor-activating agonist upon binding to the Vitamin D Receptor (VDR), a nuclear receptor present in numerous target tissues, including the intestine, bone, and kidney. The calcitriol-VDR complex heterodimerizes with the Retinoid X Receptor (RXR) and subsequently translocates to the nucleus to bind to Vitamin D Response Elements (VDREs) on the genome. This molecular interaction modulates the transcription of various vitamin D-dependent genes. Downstream consequences include increased expression of proteins essential for mineral handling, such as intestinal calcium transport proteins (e.g., TRPV6 and calbindin). At the systemic level, this action results in the modulation of circulating calcium and phosphate concentrations, a core physiological role for maintaining mineral homeostasis.

Dosage and Administration Information

The administration of Calciferol BD, whose active ingredient is Dihydrotachysterol (DHT), is officially standardized as an oral treatment. The medicine is available for consumption as tablets in strengths of 0.125 mg, 0.2 mg, and 0.4 mg, or as a concentrated oral solution (0.2 mg/ mL).

The dosing protocol is a two-step, once-daily regimen that is customized for each individual. Treatment begins with a higher Initial Dose that ranges from 0.8 mg to 2.4 mg daily, which is administered for a limited period of several days. Following this loading phase, the regimen transitions to a Maintenance Dose that typically falls between 0.2 mg and 1.0 mg daily, with an average dose often cited as 0.6 mg daily, for long-term use.

Specific dosage schedules are established for pediatric populations, including neonates, infants, and children, to meet varied needs. The official prescribing information mandates that dose adjustments, which are performed slowly over intervals of 4 to 8 weeks, must be guided by regular laboratory determination of blood calcium levels. As a condition of use for this class of medicine, patients often require adequate calcium intake through diet or supplementation to support the therapeutic goals.

Recent Clinical Evidence

Research evidence / Overview of Studies for Calciferol BD

Evidence for Use in Hypoparathyroidism

Research has focused on individuals with hypoparathyroidism, characterized by a systemic or functional imbalance in calcium levels. Studies utilized a mix of randomized controlled trials (RCTs) and long-term observational cohort studies to examine the use of this drug in adults and children with low PTH. The primary outcomes researchers examined were the patterns of change in blood markers such as serum calcium and Parathyroid Hormone (PTH) levels, alongside assessments of long-term systemic measures like renal function status.

Findings describe patterns observed in the studies, particularly aiming for the normalization of serum calcium used in research exploring how symptoms change over time. The body of high-quality, contemporary RCT evidence remains limited compared to historical data, and long-term effects are not fully established. A limitation consistently reported in studies is the narrow difference between the concentration studied for correction and the level associated with over-correction, emphasizing that frequent monitoring was a consistent focus of the research.


Evidence for Use in Chronic Kidney Disease and Renal Osteodystrophy

This part outlines the studies, such as comparative randomized trials, that specifically examined Calciferol BD in patients with advanced chronic kidney disease and related metabolic bone disorders. Calciferol BD was evaluated in populations where the kidney’s ability to activate traditional Vitamin D is often impaired. Studies explored changes in intact Parathyroid Hormone (iPTH) levels, which are commonly elevated in these conditions, as well as serum calcium and phosphate balance.

Follow-up durations were typically limited to intermediate-term trials (six months to one year). Research indicates that the risk of increasing calcium levels in the blood to a concerning degree was associated with both Dihydrotachysterol and another active Vitamin D analog, emphasizing that careful follow-up of renal function was a consistent focus of the research.


What Remains Uncertain About Calciferol BD Evidence

The certainty remains low in several areas because comparative evidence is lacking, and sample sizes were modest in many studies. Research highlights that Dihydrotachysterol was primarily studied in contexts involving its renal-activation independent pathway, rather than as a general option for nutritional deficiency. Data for certain groups, particularly concerning long-term effects beyond several years of treatment, remain insufficient, and the results apply only to the populations studied.

Frequently Asked Questions (FAQ)

Common questions about Calciferol BD (FAQ)

Q: What specific approved conditions is Calciferol BD intended to treat?

According to the official product information, this medicine is indicated for managing low calcium levels (hypocalcemia). This includes hypocalcemia associated with conditions like hypoparathyroidism and pseudohypoparathyroidism. It is also used in the treatment of a specific bone disorder called familial hypophosphatemia.

Q: Is Calciferol BD used for general wellness or only for deficiency?

Official indications establish that Calciferol BD is intended for specific therapeutic needs, not general nutritional or wellness supplementation. It is used to manage specific low-calcium conditions such as hypoparathyroidism. Its purpose is tied to medical management rather than daily maintenance.

Q: What does the term "refractory rickets" mean in the context of Calciferol BD use?

Regulatory documentation explicitly lists the treatment of familial hypophosphatemia as an indication for this medicine. This condition is also commonly known as Vitamin D-resistant rickets or refractory rickets, referring to rickets that does not respond to standard doses of Vitamin D.

Q: Is Calciferol BD meant to replace sun exposure or diet?

The official labeling establishes that the medicine is used for specific hypocalcemic conditions and is not indicated as a replacement for general nutritional intake. The prescribing information notes that adequate calcium intake through diet or supplementation is required to support the therapeutic goals.

Q: What happens if I forget a dose of Calciferol BD?

Patient information typically describes a procedure for a missed dose. Generally, the procedure states that if a dose is missed, the patient may take it as soon as it is remembered, unless it is nearly time for the next scheduled dose. The regulatory instruction typically advises against taking two doses at once.

Q: Can Calciferol BD be safely taken while driving or operating machinery?

Official regulatory documents contain an explicit statement that addresses whether the medicine has any known effects on the ability to drive or operate machinery. This information is based on the drug's safety profile, particularly the potential for side effects such as vertigo or dizziness.

Q: Does Calciferol BD contain common allergens like peanut oil or soy?

The complete list of inactive ingredients (excipients) used in the formulation is formally documented in the regulatory product information. This list details all components, including specific oils or potential allergens, for patient safety.

Q: How does Calciferol BD work in the body to help with bones?

Official information describes the active ingredient, Dihydrotachysterol, as a Calcium Regulator. This medicine is classified as a bone density conservation agent. It works by modulating the levels of calcium and phosphate in the body, which affects the mobilization of calcium from the bone structure to maintain mineral balance.

Q: What is the difference between Calciferol BD and other high-strength Vitamin D treatments?

The active component, Dihydrotachysterol, is described as a unique Vitamin D analog. Unlike standard forms of Vitamin D that require two steps to become active, Dihydrotachysterol does not rely on the second step in the kidneys (renal-activation independent). This distinction is key to its use in certain patient populations where kidney activation is impaired.

Q: Is it safe to use Calciferol BD with other medications for high blood pressure?

The official product label notes an interaction with thiazide diuretics, a type of high blood pressure medication. This combination may increase the risk of high blood calcium levels (hypercalcemia). Information regarding the use of Calciferol BD with other classes of blood pressure medication is not typically detailed in the official prescribing information.

Q: What kind of symptoms are associated with Vitamin D deficiency that Calciferol BD is supposed to address?

The medicine’s general purpose is to act as an Anti-tetany Substance. Tetany is a condition involving involuntary muscle spasms and is a severe neurological symptom often associated with very low blood calcium levels. Its use is therefore tied to correcting severe mineral imbalances that lead to such symptoms.

Q: Can Calciferol BD be taken at the same time as antacids?

Regulatory information notes that for patients with kidney failure, the concurrent use of large doses of magnesium-containing antacids may lead to an excess of magnesium in the blood (hypermagnesemia). This is a safety consideration for individuals with impaired renal function.

Q: Does mineral oil interfere with how Calciferol BD is absorbed?

Official regulatory documents specifically state that the bile acid sequestrant cholestyramine formally impairs the intestinal absorption of Dihydrotachysterol. However, most regulatory information does not typically list specific interactions with substances such as mineral oil.

Q: How quickly do blood levels change after starting Calciferol BD?

Pharmacokinetic data for Dihydrotachysterol is available in regulatory documents, which defines how the medicine is absorbed and metabolized by the body. These figures, such as the time it takes to reach maximum concentration and the half-life, provide the scientific basis for how blood levels change after starting treatment.

Q: Does Calciferol BD start working immediately or is there a delay?

Regulatory documents include pharmacokinetic data which defines the time to reach maximum concentration (T₊m₊x) in the blood after administration. This figure provides a scientific measurement for the time delay before the drug reaches its maximum concentration in the body.

Q: What is the relationship between Calciferol BD and a history of developing kidney stones?

Official warnings exist concerning the risk of high blood calcium (hypercalcemia), which can lead to the formation of calcium deposits in the kidneys (Nephrocalcinosis). This information suggests caution and close monitoring for individuals who have a history of conditions related to calcium build-up, such as kidney stones.

Q: What is the clinical significance of taking Calciferol BD with a meal?

The official instructions for administration typically specify whether the medicine should be taken with food or on an empty stomach. This instruction is provided to ensure optimal absorption and effectiveness of the active ingredient.

Q: What is the typical duration of treatment with Calciferol BD for a severe deficiency?

The treatment regimen is structured with an Initial Dose that is administered for a limited period, followed by a Maintenance Dose intended for long-term use. This distinction establishes the framework for the overall duration of treatment, which is highly personalized based on laboratory monitoring.

How should Calciferol BD be stored and disposed of?

Storage and Disposal Requirements

To ensure stability and effectiveness, Calciferol BD (Dihydrotachysterol) must be stored strictly according to official regulatory labeling.

Storage Condition Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F). Do not freeze or expose to excessive heat.
Protection Protect from light and keep the product in the original, tightly closed container.
Stability (Solution) Discard the oral solution one year after the bottle is first opened.
Child Safety Keep out of the reach of children.

Unused or expired medicine must be disposed of according to local regulatory requirements. Unless instructed otherwise, the product should generally not be flushed down a toilet or poured into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Calciferol BD found in:

A-Z Index: